课题基金 / 基金详情

PHASE I TRIAL OF ADENOVIRAL VECTOR DELIVERY OF THE HERPES SIMPLEX THYMIDINE

PHASE I TRIAL OF ADENOVIRAL VECTOR DELIVERY OF THE HERPES SIMPLEX THYMIDINE
单纯疱疹病毒胸苷腺病毒载体递送的 I 期试验
批准号：
6305226
负责人：
MAX W SUNG
金额：
$6.88万
依托单位：
MOUNT SINAI SCHOOL OF MEDICINE OF CUNY
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2001-02-28
来源：
https://reporter.nih.gov/project-details/6305226
关键词：
Adenoviridae Alphaherpesvirinae clinical research clinical trial phase I combination cancer therapy ganciclovir gene therapy human subject human therapy evaluation liver neoplasms metastasis neoplasm /cancer chemotherapy thymidine kinase

项目摘要

项目成果

MAX W SUNG的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The specific aims of this proposal are to study in a Phase I trial the toxicity of escalating doses of recombinant adenoviral vector expressing the herpes simplex thymidine kinase gene (ADV-tk) administered by percutaneous intratumoral injection of metastatic hepatic tumours followed by the intravenous administration of a fixed dose of ganciclovir (GCV).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: ADENOVIRAL VECTOR DELIVERY OF THE HUMAN INTERLEUKIN-12 CDNA IN M
CLINICAL TRIAL: ADENOVIRAL VECTOR DELIVERY OF THE HUMAN INTERLEUKIN-12 CDNA IN M
TRIAL OF HUMAN INTERLEUKIN-12 CDNA IN METASTATIC COLORECTAL CANCER TO THE LIVER
PHASE I TRIAL OF ADENOVIRAL VECTOR DELIVERY OF THE HUMAN INTERLEUKIN-12 CDNA